Investors

Webcast
Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT
Webcast Presentation

Geron 2018 Annual Meeting of Stockholders
May 15, 2018 at 4:00 PM PDT

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Calvin B. Harley to Retire as Chief Scientific Officer of Geron
Continues as Senior Advisor to Company MENLO PARK, Calif., September 8, 2009 - Geron Corporation (Nasdaq: GERN) today announced that Calvin B. Harley, Ph.D., the company's chief scientific officer (CSO) for telomerase technologies, will retire on September 15, 2009. Dr.
Toggle Summary Corning Incorporated and Geron Corporation Showcase New Synthetic Surface Matrices to Enhance Stem Cell Growth
Results of collaborative research to be shared at 2009 World Stem Cell Summit CORNING, N.Y. & MENLO PARK, Calif., September 21, 2009 - Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to
Toggle Summary Data Show Geron´s Cell-Based Therapeutic for Spinal Cord Injury Survives and Exhibits Remyelination for at Least Nine Months Following Injection
Study Also Shows GRNOPC1 Does Not Amplify Neuropathic Pain Like Other Neural Progenitor Cells Injected into Spinal Cord MENLO PARK, Calif., Nov. 7, 2007 – Geron Corporation (Nasdaq: GERN) today announced that data show GRNOPC1, the company’s human embryonic stem cell (hESC)–based therapeutic for

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com